Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Antibodies 2013, 2(1), 82-92; doi:10.3390/antib2010082
Review

An Old Idea Tackling a New Problem: Targeted Toxins Specific for Cancer Stem Cells

1 and 2,*
Received: 6 December 2012; in revised form: 19 January 2013 / Accepted: 22 January 2013 / Published: 28 January 2013
(This article belongs to the Special Issue Recombinant Immunotoxins)
View Full-Text   |   Download PDF [169 KB, uploaded 28 January 2013]
Abstract: Targeting and killing specific cells discriminately has been the goal of targeted therapy dating back to the era of Paul Ehrlich. The discovery of cancer stem cells has caused a paradigm shift within the cancer field and provided an opportunity to use targeted therapies such as targeted toxins to bind and kill these cells selectively. A number of targeted toxins have been developed against recently identified cancer stem cell markers. In this review we discuss the development and current status of these exciting novel drugs and their potential use to combat drug-refractory relapse.
Keywords: cancer stem cells; targeted toxins; immunotoxins; CD133; EpCAM; CD123; CD44 cancer stem cells; targeted toxins; immunotoxins; CD133; EpCAM; CD123; CD44
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Waldron, N.N.; Vallera, D.A. An Old Idea Tackling a New Problem: Targeted Toxins Specific for Cancer Stem Cells. Antibodies 2013, 2, 82-92.

AMA Style

Waldron NN, Vallera DA. An Old Idea Tackling a New Problem: Targeted Toxins Specific for Cancer Stem Cells. Antibodies. 2013; 2(1):82-92.

Chicago/Turabian Style

Waldron, Nate N.; Vallera, Daniel A. 2013. "An Old Idea Tackling a New Problem: Targeted Toxins Specific for Cancer Stem Cells." Antibodies 2, no. 1: 82-92.

Antibodies EISSN 2073-4468 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert